Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jul 6;144(15):1617–1632. doi: 10.1182/blood.2023023727

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 International (CC BY-NC-ND 3.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 5. — Genetic heterogeneity of s/t-MDS. (A) Prevalence of molecular groups in 267 patients with s/t-MDS. (B) Proportion of primary (red) and s/t-MDS (blue) within each molecular group and comparison with the full cohort (top). (C) Distribution of the number of mutated genes per patient in primary or s/t-MDS within each molecular group (TP53-complex, −7/SETBP1, SF3B1, and IDH-STAG2), showing similar molecular complexity of the 2 disease subsets. For example, the median number of mutated genes per patient was equal to 2 for both primary and s/t-MDS within TP53-complex, whereas it was equal to 5 for both subsets within IDH-STAG2. (D) Age distribution in primary or s/t-MDS within each molecular group. (E) Kaplan-Meier probability estimates of OS for primary or s/t-MDS within each molecular group. P values are from the log-rank test.

Figure 5. — Genetic heterogeneity of s/t-MDS. (A) Prevalence of molecular groups in 267 patients with s/t-MDS. (B) Proportion of primary (red) and s/t-MDS (blue) within each molecular group and comparison with the full cohort (top). (C) Distribution of the number of mutated genes per patient in primary or s/t-MDS within each molecular group (TP53-complex, −7/SETBP1, SF3B1, and IDH-STAG2), showing similar molecular complexity of the 2 disease subsets. For example, the median number of mutated genes per patient was equal to 2 for both primary and s/t-MDS within TP53-complex, whereas it was equal to 5 for both subsets within IDH-STAG2. (D) Age distribution in primary or s/t-MDS within each molecular group. (E) Kaplan-Meier probability estimates of OS for primary or s/t-MDS within each molecular group. P values are from the log-rank test.